

Registration Assessment Sample Papers – Spring 2012
Answers and Guidance notes

Closed Book

Question	Answer	Comments
1	E	The clinicians' section of Patient.co.uk provides a useful summary of presenting symptoms, including a section on differential diagnosis. http://www.patient.co.uk/doctor/Shingles.htm
2	D	Waste management arrangements in England and Wales are enforced by the Environment Agency www.environment-agency.gov.uk and in Scotland by the Scottish Environment Protection Agency www.sepa.org.uk Information is also available in a publication entitled 'Safe management of healthcare waste' available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_126345
3	E	The plasma elimination half-life of a drug is the time it takes for 50% of medicine present in the plasma to be eliminated, therefore after 2 half-lives 75% of a medicine will have been eliminated.
4	D	See individual monographs in BNF.
5	C	BNF Section 6.1.3 – Diabetic ketoacidosis.
6	B	See BNF Appendix 1 and 'Stockley's Drug Interactions'.
7	C	See BNF Section 5.1.9 – Antituberculosis drugs.
8	C	See BNF Section 2.4 – Beta-adrenoceptor blocking drugs.
9	A	Medicines returned to a pharmacy from a patient's home must not be supplied to any other patient. A summary of guidance on the management of Controlled Drugs (including destruction in Section 10) is provided by the NHS National Prescribing Centre at: http://www.npc.nhs.uk/controlled_drugs/resources/controlled_drugs_third_edition.pdf
10	E	See BNF Appendix 1 and 'Stockley's Drug Interactions'.
11	D	See BNF Section 1.5.1 – Aminosalicylates.
12	A	See BNF Section 2.2.1 – Bendroflumethiazide.
13	B	The clinicians' section of Patient.co.uk provides a useful summary of presenting symptoms, including a section on differential diagnosis.

Question	Answer	Comments
		http://www.patient.co.uk/doctor/Dermatophytosis-(Tinea).htm
14	E	See BNF Section 9.6.6 – Vitamin K.
15	D	See BNF Section 9.6.4 – Vitamin D.
16	D	See BNF Section 2.6.2 – Calcium-channel blockers.
17	E	See BNF Section 2.12 – Statins.
18	C	The clinicians' section of Patient.co.uk provides a useful summary of presenting symptoms, including a section on management. http://www.patient.co.uk/doctor/Hyperthyroidism-(Thyrotoxicosis).htm
19	D	See BNF section 5.1.5 - Macrolides
20	A	See BNF Section 10.1.1 – NSAIDs.
21	A	See BNF Section 5.1.1.2 – Flucloxacillin.
22	B	See BNF Section 5.1.3 – Tetracyclines.
23	D	See BNF Section 5.1.12 – Ciprofloxacin.
24	C	See BNF Section 5.1.11 – Metronidazole and tinidazole.
25	B	See BNF Section 9.1.2 (Prevention of neural tube defects) and Section 4.8.1 (Control of epilepsy – pregnancy and breast-feeding).
26	D	See individual monographs in BNF.
27	E	See BNF Guidance on prescribing: Emergency supply of medicines.
28	A	See BNF Guidance on prescribing: Prescribing in renal impairment.
29	C	The clinicians' section of Patient.co.uk provides a useful summary of the condition, including a section on risk factors. http://www.patient.co.uk/doctor/Candidiasis.htm
30	C	In England: Department of Health Clinical Governance Guidance http://www.dh.gov.uk/health/search/?searchTerms=Clinical+governance In Wales: Clinical Governance Support & Development Unit http://www.wales.nhs.uk/sites3/home.cfm?orgid=419 In Scotland: Clinical Governance http://www.clinicalgovernance.scot.nhs.uk/
31	B	The clinicians' section of Patient.co.uk provides a useful summary of the condition, including a section on differential diagnosis and symptoms requiring urgent referral. http://www.patient.co.uk/doctor/Dyspepsia.htm

Question	Answer	Comments
32	B	The clinicians' section of Patient.co.uk provides a useful summary of the condition, including a section on risk factors and presentation. http://www.patient.co.uk/doctor/Upper-Gastrointestinal-Bleeding.htm See also BNF Section 9.1.1.1 – Oral iron.
33	C	See GPhC <i>Standards of conduct, ethics and performance</i> .
34	D	See individual monographs in BNF.
35	B	See individual monographs in BNF.
36	C	See BNF Section 5.4.1 – Protection against malaria.
37	D	See GPhC <i>Standards of conduct, ethics and performance</i> , and GPhC <i>Guidance on the provision of pharmacy services affected by religious and moral beliefs</i> .
38	D	See BNF Section 5.1 – Antibacterial drugs: Choice of a suitable drug.
39	B	See BNF Section 5.1 – Table 1: Summary of antibacterial therapy.
40	A	See notes above relating to sources for Q-30.
41	E	See NHS Direct web site: http://www.nhsdirect.nhs.uk/ or NHS 24 (Scotland) web site: http://www.nhs24.com/
42	C	See BNF Guidance on Prescribing: Prescribing for Children.
43	B	See BNF Section 3.4.1 – Antihistamines
44	E	See PSNC guide on the audit cycle in the context of the community pharmacy contract. http://www.psn.org.uk/data/files/PharmacyContractandServices/ClinicalGovernance/a_guide_to_clinical_audit.pdf
45	E	See BNF Guidance on Prescribing: Prescription writing.

Registration Assessment Sample Papers – Spring 2012
Answers and Guidance notes

Open Book

Question	Answer	Comments
1	B	See individual monographs in BNF.
2	E	See BNF Section 9.2.1.1 – Calcium Resonium®, and BNF Section 2.2.3 – Spironolactone.
3	A	See BNF Guidance on prescribing: Controlled Drugs and drug dependence.
4	C	See BNF Section 9.8.2 – Acute porphyrias: Drugs unsafe for use in acute porphyrias.
5	D	See individual monographs in BNF.
6	C	See individual monographs in BNF.
7	A	See BNF Section 5.5.1 – Drugs for threadworms.
8	D	See BNF Section 7.3.1 – Reasons to stop immediately.
9	D	See BNF General information and changes for this edition: How to use the BNF, and individual monographs.
10	B	See BNF Section 2.4 – Beta-adrenoceptor blocking drugs.
11	B	See BNF Section 5.4.1 – Prophylaxis against malaria.
12	A	See BNF Section 5.4.1 – Prophylaxis against malaria.
13	E	See BNF Section 5.4.1 – Prophylaxis against malaria.
14	B	See BNF Guidance on prescribing: Controlled Drugs and drug dependence.
15	D	See BNF Guidance on prescribing: Controlled Drugs and drug dependence.
16	C	See BNF Guidance on prescribing: Controlled Drugs and drug dependence.
17	C	See GPhC <i>Standards of conduct, ethics and performance</i> , and GPhC <i>Guidance on patient confidentiality</i>
18	C	See BNF Section 6.3.2 – Glucocorticoid therapy: Pregnancy and breast-feeding.

Question	Answer	Comments
19	A	See BNF Appendix 2 – Borderline substances
20	E	See individual monographs in BNF.
21	A	See GPhC <i>Standards of conduct, ethics and performance</i> .
22	B	See individual monographs in BNF.
23	C	See individual monographs in BNF.
24	D	See BNF Section 5.1 – Table 1 Summary of antibacterial therapy
25	D	See BNF Section 2.8.2 – Oral anticoagulants
26	C	See BNF Appendix 1: Interactions - anticoagulants - coumarins
27	A	See BNF Appendix 1: Interactions - anticoagulants - coumarins, and 'Stockley's Drug Interactions'
28	E	See BNF Section 11.8.1 – Tear deficiency, ocular lubricants, and astringents: Hypromellose eye drops.
29	E	See BNF – Emergency treatment of poisoning.
30	A	See BNF Section 4.7.2 –Opioid analgesics: Buprenorphine
Calculations section		
31(Calc)	E	<p>Haelan® cream contains fludroxycortide cream 0.0125%</p> <p>∴ 0.0125 g in 100 g</p> <p>∴ 12.5 mg in 100 g</p> <p>∴ 12.5 mg ÷ 5</p> <p>= 2.5 mg in 20 g</p>
32(Calc)	B	<p>Oily Phenol Injection BP contains 5% phenol</p> <p>∴ 5 g in 100 mL</p> <p>The patient is given 3 injections of 3 mL</p> <p>∴ total given = 9 mL</p> <p>∴ 5 g in 100 mL</p> <p>∴ 5000 mg in 100 mL</p> <p>∴ 500 mg in 10 mL</p> <p>∴ 450 mg in 9 mL</p>
33(Calc)	A	<p>FluoriGard® Daily dental rinse contains 0.05% sodium fluoride</p> <p>∴ 0.05 g in 100 mL</p> <p>∴ 50 mg in 100 mL</p> <p>∴ 5 mg sodium fluoride in 10 mL</p> <p>Sodium fluoride 2.2 mg = 1 mg fluoride ion</p>

Question	Answer	Comments
		$\therefore 5 \text{ mg} \div 2.2 = 2.27 \text{ mg fluoride ion}$
34(Calc)	E	You are required to prepare a total of 15 powders, each containing 6 mg propranolol \therefore the total weight of propranolol required is 90 mg (15 x 6) The final weight of each powder is 250 mg, \therefore the weight of lactose required for each powder is 244 mg (250 – 6) The total weight of lactose required is 3660 mg (244 x 15) = 3.66 g
35(Calc)	A	240 mg over 24 hours \therefore 10mg/hour Morphine 20 mg/mL \therefore 0.5 mL/hour
36(Calc)	C	The maximum recommended dose is 6 mg/kg/day in 3 divided doses \therefore the maximum daily dose for a of 22 kg child = 132 mg (6 x 22) = 44 mg tds The gentamicin injection contains 80 mg in 2 mL \therefore 40 mg in 1 mL \therefore 44 mg in 1.1 mL
37(Calc)	D	The oxygen cylinder contains 1360 litres \therefore if used at 2 litres/minute the cylinder will last for 680 minutes (1360 \div 2) 680 minutes = 11 hours 20 minutes
38(Calc)	E	15% solution contains 15 g in 100 mL \therefore 90 g in 600 mL
39(Calc)	B	The original solution prior to dilution will be 45 mL of a 0.2% solution \therefore when diluted with an equal volume of water will give 90 mL of a 0.1% solution \therefore 0.1% solution contains 0.1 g in 100 mL \therefore 0.09 g in 90 mL
40(Calc)	A	1) 1 mole of sodium bicarbonate weighs 84 g \therefore 1 mmol = 84 mg \therefore 150 mmol = 12600 mg (84 x 150) = 12.6 g 2) 1 mole of sodium chloride weighs 58.5 g \therefore 1 mmol = 58.5 mg \therefore 100 mmol = 5850 mg (58.5 x 100) = 5.85 g 3) 1 mole of potassium chloride weighs 74.5 g \therefore 1 mmol = 74.5 mg \therefore 40 mmol = 2980 mg (74.5 x 40) = 2.98 g